30 closest matches · ranked by relevance
Measles Antibody Seroconversion · Rubella Antibody Seroconversion · Rotavirus Geometric Mean Titer (GMT)
Primary: Percentage/Number of Subjects With Seroprotection for Measles Virus Serum Neutralization Antibodies — 171; 173; 56; 60 Participants
Pertussis Infection
Primary: IgG — 1.254; 1.258 EU/mL(log transformed)
Japanese Encephalitis · Measles · Mumps
Primary: Percentage of Participants With Seroconversion to Vaccine Antigens Following Concomitant Administration of Japanese Encephalitis Chimeric Virus Vaccine (JECV) and MMR or…
Measles · Rubella · Rubella Syndrome, Congenital
Primary: Percent of Infants Who Were Seropositive After Immunization at 6 Months (Assessed at 9-month Visit) — 94; 94 percentage of infants
Japanese Encephalitis
Primary: Number and Percentage of Subjects With Demonstrated Seropositivity for Japanese Encephalitis (JE) Neutralizing Antibodies — 14; 243; 233; 24 Participants
COVID · Corona Virus Infection · Multisystem Inflammatory Syndrome in Children
Primary: Immunoglobulins (G and M) to SARS-Cov2 in Plasma — 4.86; 65.32; 64.17 Titres
Hepatitis A · Measles · Mumps
Primary: Participants With 1 or More Serious Vaccine-Related Adverse Experiences — 0; 1 participants
Rubella · Mumps · Measles
Primary: Number of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value. — 245; 236; 236; 248 Subjects
Measles/Rubella
Primary: Number of Participants With Serious Adverse Drug Reactions (ADRs) — 2 Participants
Meningococcal Disease · Meningococcal Meningitis
Primary: Percentage of Subjects With hSBA Titers ≥1:4 Against Meningococcal Strains, At 18 Months After Month-6 Vaccination in V72P10 Study, and in Naive Subjects. — 31; 40; 40…
Meningococcal Disease
Primary: Geometric Mean Titers (GMTs) to Assess Antibody Persistence at 12 Months After a Booster Dose of rMenB+OMV NZ Vaccination. — 7.38; 8.3; 6.5; 68 Titers
Measles/Rubella
Primary: Number of Participants With Serious Adverse Drug Reactions — 7 participants
Japanese Encephalitis
Primary: Seroconversion Rate — 98.5 percent
Encephalitis, Tick-Borne
Primary: Seropositivity Rate Measured by Neutralization Test (NT) at 21-35 Days After the First Tick-borne Encephalitis (TBE) Booster Vaccination in Study 700401 — 100.0…
Measles · Varicella · Mumps
Primary: Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Antibodies Greater Than or Equal to (≥) the Cut-off Value. — 312; 157; 279; 142 Participants
Meningococcal Disease
Primary: Summary of Memory B Cells Per 2 x 105 LOC by Serogroup A, C, W-135 and Y — 2.10; 1.80; 1.72; 2.57 B cells per 2x100000 lymphocytes — p=0.69
Meningococcal Disease
Primary: Percentage of Subjects With Persisting Serum Bactericidal Antibody Titers ≥1:8, Upto 13-33 Months After Primary Vaccination With Either MenACWY-CRM or MenC Vaccine — 13…
Rubella · Mumps · Measles
Primary: Anti-measles Virus Antibody Concentrations. — 1795.6; 1783.3 mIU/mL
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Primary: Percentage of Participants With Meningococcal Antibody Titers ≥ 1:4 Before, 28 Days After, and Approximately Four Years Following Menactra Vaccine Booster Vaccination…
Meningitis · Meningococcal Infection
Primary: Percentage of Participants With Serum Bactericidal Activity of ≥ 1:8 for the Menactra® Meningococcal Serogroups Pre-vaccination, and at 7 Days or 14 Days Post-booster or…
Meningitis · Meningococcemia
Primary: Geometric Mean of Antibody Titers (GMTs) as Measured by Serum Bactericidal Assay (SBA) at Baseline (Day 0) and Day 28 Post-vaccination. — 136.33; 99.66; 11404.16; 199.31…
Haemophilus Influenzae Type b · Neisseria Meningitidis · Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine
Primary: Number of Subjects With Serum Bactericidal Assay Using Baby Rabbit Complement (rSBA-MenC) Antibody Titers Equal to or Above 1:8 — 12; 3; 200; 63 Subjects
Measles; Mumps; Rubella · Measles-Mumps-Rubella Vaccine
Primary: Number of Subjects Reporting Fever After MMR (Priorix or M-M-R II/M-M-R VaxPro [Lot 1 or Lot 2]) Vaccination — 47; 17; 205; 95 Participants
Varicella · Rubella · Mumps
Primary: Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Antibodies — 149; 153; 72; 149 Participants
Non-target Heterologous Effects of Vaccines · Vaccine Interactions
Primary: Effect on Interferon (IFN)-Gamma : Interleukin (IL)-4 Ratio in Plasma — 1.48; 1.44; 0.46 ratio of cytokines in pg/mL
Measles; Mumps; Rubella; Chickenpox · Measles
Primary: GMC of Anti-measles Antibodies at Day 43 — 801; 788; 728; 682 mIU/mL
Varicella · Chickenpox Vaccines
Primary: Phase A: Number of Subjects With Confirmed Varicella Case — 37; 243; 201 Participants — p=<0.0001
Hepatitis B
Primary: Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations — 87.6; 43.8; 143.4; 34.4 mIU/mL
Pertussis · Pregnancy Related
Primary: The Seroprevalence of Anti-pertussis Toxin Antibodies (Anti-PT IgG) in Pregnant Thai Women — 43 Participants
Sepsis Syndrome
Primary: Induction of MDSCs — 0.19; 0.11 fold change compared to baseline